Literature DB >> 8121190

Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas.

T Hoshi1, M Imai, K Ogawa.   

Abstract

Mucin-producing tumors of the pancreas (MPT) are characterized by the production of much mucin and a benign course after surgical treatment. We examined 16 cases of MPT and 20 cases of "common" pancreatic duct cell carcinomas (DCC) in regard to K-ras and p53 mutations. The mutations were detected by constant denaturant gel electrophoresis in combination with other techniques using PCR products amplified from the samples microdissected from the tissue sections. K-ras codon 12 mutations were identified in all MPT and in 95% of DCC. On the other hand, p53 mutations were found in four of 20 (20%) DCC, and p53 was immunocytochemically overexpressed in 3 of the 4 mutated cases. However, no p53 mutations and no p53 overexpression were identified in the 16 MPT. These results indicate that, although the K-ras codon 12 mutations may be almost essential for the development of both MPT and DCC, p53 mutations seemed to be involved mainly to the latters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8121190     DOI: 10.1002/jso.2930550205

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Mucinous cystadenocarcinoma of the spleen presenting a point mutation of the Kirsten-ras oncogene at codon 12.

Authors:  M Hirota; N Hayashi; T Tomioka; S Murakami; H Ohshima; K Yamasaki; J Miyamoto; S Tamiya; M Ogawa
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

Review 2.  Current and emerging treatments for pancreatic cancer.

Authors:  W F Regine; W J John; M Mohiuddin
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

3.  Precursor lesions of pancreatic cancer.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Masamichi Goto
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

Review 4.  Molecular biology of exocrine pancreatic cancer.

Authors:  J L Soto; V M Barbera; M Saceda; A Carrato
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

5.  Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  H Fujii; M Inagaki; S Kasai; N Miyokawa; Y Tokusashi; E Gabrielson; R H Hruban
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

6.  Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.

Authors:  K Z'graggen; J A Rivera; C C Compton; M Pins; J Werner; C Fernández-del Castillo; D W Rattner; K B Lewandrowski; A K Rustgi; A L Warshaw
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

7.  Risk of additional pancreatic cancer in patients with branch duct intraductal papillary-mucinous neoplasm.

Authors:  Satoshi Tanno; Takeshi Obara; Kazuya Koizumi; Yasuhiro Nakano; Manabu Osanai; Yusuke Mizukami; Yutaka Kohgo
Journal:  Clin J Gastroenterol       Date:  2009-10-30

8.  Does "clonal progression" relate to the development of intraductal papillary mucinous tumors of the pancreas?

Authors:  Keita Wada; Tadahiro Takada; Hideki Yasuda; Hodaka Amano; Masahiro Yoshida; Maki Sugimoto; Hiroshi Irie
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

Review 9.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

10.  Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms.

Authors:  M Tobi; J Hatfield; V Adsay; K Galagan; R Kozarek; M Inagaki; S Kasai; Y Tokusashi; T Obara; R H Hruban; J Lough; A N Barkun; M Jabbari; R Sheikh; B Ruebner; M J Lawson; E Ben-Josef; S Fligiel
Journal:  Int J Pancreatol       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.